The treatment of Ozone along with the standard of care in mild to moderate patients of COVID 19 provided a clinical advantage over only standard of care treatment. There was improved SPO₂, clinical symptoms status. There was faster viral eradication from host cells. 77% of subjects from the ozone-treated group were RT-PCR negative on day 5 and 100% subjects were RT-PCR negative on day 10.  There was a significant reduction in clinical symptoms like cough and breathlessness in ozone-treated subjects. X-ray investigations revealed a fact that there is a resolution of pulmonary infiltration in 5 to 10 days of treatment of ozone therapy along with the standard of care in consensus with their RT-PCR negativity. The inflammatory markers like CRP, LDH, and ferritin were reduced more in magnitude than the standard group indicating that the patient is protected through anti-inflammatory activity to halt the progression of the disease. Ozone treatment has reduced the hospital stay of patients. The quality of life of patients was very much improved in ozone-treated patients than that of the standard treatment alone. 10% of subjects from the standard of care were in requirement of ICU admission and artificial ventilation of which two patients progressed to death. In ozone-treated group there were 100% subjects on air and no requirement of oxygen supplementation and ICU. No fatality in the ozone-treated group. There was 100% compliance of patients to ozone therapy with a zero dropout rate. All the biochemical markers like liver, lipid, and kidney function tests for patients with both groups were within normal range throughout the study. It indicates the safety of the ozone therapy in COVID 19 patients. Overall Ozone Therapy was found to be a safe and effective choice in the management of patients presenting mild to moderate clinical presentation of COVID 19 in 10 days’ treatment.